Clin Asst Prof Tan Ya Hwee

Dr. Tan is a Medical Oncologist with expertise in lymphoma, sarcoma, skin cancers, and cellular therapy. She is an active clinical trialist, involved in both early and late-phase studies, novel drug development, and advanced therapeutic platforms including T-cell engagers and cellular therapies.

Her clinical and research interests are in immuno-oncology, with a focus on the development and application of cellular therapies. She is actively involved in collaborative research and clinical trials, working to translate emerging immunotherapies into patient care.

Dr. Tan was awarded the Ministry of Health's Health Manpower Development Plan (HMDP) award in 2024 to support advanced training in adoptive cell therapy for solid tumours. She has undergone fellowship training at leading international centres, including the Netherlands Cancer Institute (NKI) in Amsterdam and the Peter MacCallum Cancer Centre in Melbourne, where she gained experience in tumour-infiltrating lymphocyte (TIL) therapy and novel chimeric antigen receptor T-cell (CAR-T) approaches in solid tumours, alongside early drug development and novel therapeutics.

She is currently pursuing a Master of Integrated Immunology at the University of Oxford, reflecting her commitment to integrating scientific advances with clinical care.

Dr. Tan is committed to delivering personalised, patient-centred cancer care while advancing innovative treatment strategies through clinical research.

• 2024 Ministry of Health-SingHealth Health Manpower Development Plan Award Fellowship in Adoptive cell therapy in solid tumour at Peter MacCallum Cancer Centre, Australia 
• 2024 American Society of Hematology Clinical Research Training Institute (ASH-CRTI) Award 
• 2023 SingHealth Quality Service Award - Gold Award 
• 2022 SingHealth Quality Service Award - Sliver Award 
• 2020 Medical Oncology Specialist Exit Exam - Book Prize Award

• Tan, Y.H., Yoon, D.H., Davies, A.J. et al. Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia. Discov Onc 16, 181 (2025). 
• Chang, E.W.Y., Tan, Y.H. & Chan, J.Y. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma. J Hematol Oncol 17, 38 (2024). 
• Yau CE, Low CE, Ong WS, Khoo LP, Hoe JTM, Tan YH, Chang EWY, Yang VS, Poon EYL, Chan JY, et al. Using Deauville Scoring to Guide Consolidative Radiotherapy in Diffuse Large B-Cell Lym-phoma. Cancers. 2024; 16(19):3311 
• Chua BJG, Low CE, Yau CE, Tan YH, Chiang J, Chang EWY, Chan JY, Poon EYL, Somasundaram N, Harunal Rashid MFB, Tao M, Lim ST, Yang VS. Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma. Exp Hematol Oncol13, 1 (2024) 
• Tan JY, Qiu TY, Chiang J, Tan YH, Chan YJ et al. Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2022 Feb 19:1-11. 
• Teo YH, Teo YN, Khoo LP, Chang EWY, Tan YH, Chiang J, Yang VS, Poon E, Somasundaram N, Fa-rid M, Tao M, Lim ST, Chan JY. Clinicopathological factors affecting prognosis in marginal zone lymphoma in Asian patients: a cohort study. Leuk Lymphoma. 2022 Jun 10:1-4. doi: 10.1080/10428194.2022.2086242 
• Lo YT, Lim VY, Ng M, Tan YH, Chiang J, Chang EWY, Chan JY, Poon EYL, Somasundaram N, Bin Harunal Rashid MF, Tao M, Lim ST, Yang VS. A Prognostic Model Using Post-Steroid Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Primary Central Nervous System Lymphoma. Can-cers (Basel). 2022 Apr 3;14(7):1818. 
• Tan GF, Goh S, Chang EW, Tan YH, Chiang J, Yang VS, Poon EY, Somasundaram N, Rashid MF, Tao M, Lim ST. Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin’s Lymphoma. Hematology Reports. 2023 Mar;15(1):108 
• Ng DZ, Lee CY, Lam WW, Tong AK, Tan SH, Khoo LP, Tan YH, Chiang J, Chang EW, Chan JY, Poon EY, Somasundaram N, Farid H Rashid M, Tao M, Lim ST, Yang VS. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evalua-tion: a comparison of the Deauville 5-point scale and the ΔSUVmax method. Leuk Lymphoma. 2021 Oct 19:1-4 
• CSW Tham, Tan YH, Yang VS, et al. An unusual presentation of lymphoma. Curr Probl Cancer Case Rep. 2021;4:100080. doi: 10.1016/j.cpccr.2021.100080. 
• Tan JY, Qiu TY, Chiang J, Tan YH, Chan YJ et al. Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma. J Hematol. 2020;10(4):187-195.